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Abstract
Although chronic hypoxia is a claimed myocardial risk factor reducing tolerance to ischemia/reperfusion (I/R), intermittent
reoxygenation has beneficial effects and enhances heart tolerance to I/R. Aim of the study: To test the hypothesis that, by
mimicking intermittent reoxygenation, selective inhibition of phosphodiesterase-5 activity improves ischemia tolerance
during hypoxia. Adult male Sprague-Dawley rats were exposed to hypoxia for 15 days (10% O2) and treated with placebo,
sildenafil (1.4 mg/kg/day, i. p.), intermittent reoxygenation (1 h/day exposure to room air) or both. Controls were normoxic
hearts. To assess tolerance to I/R all hearts were subjected to 30-min regional ischemia by left anterior descending coronary
artery ligation followed by 3 h-reperfusion. Whereas hypoxia depressed tolerance to I/R, both sildenafil and intermittent
reoxygenation reduced the infarct size without exhibiting cumulative effects. The changes in myocardial cGMP, apoptosis
(DNA fragmentation), caspase-3 activity (alternative marker for cardiomyocyte apoptosis), eNOS phosphorylation and Akt
activity paralleled the changes in cardioprotection. However, the level of plasma nitrates and nitrites was higher in the
sildenafil+intermittent reoxygenation than sildenafil and intermittent reoxygenation groups, whereas total eNOS and Akt
proteins were unchanged throughout. Conclusions: Sildenafil administration has the potential to mimic the cardioprotective
effects led by intermittent reoxygenation, thereby opening the possibility to treat patients unable to be reoxygenated through
a pharmacological modulation of NO-dependent mechanisms.
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Introduction
Systemic hypoxia, or insufficient supply of O2 to tissues, is a
common denominator in several diseases, including myocardial
infarction, cyanotic congenital heart defects, pulmonary obstruc-
tive diseases and chronic cor pulmonale. Among these diseases, all
of which reflect into systemic hypoxia, infants and children with
congenital cyanotic heart defects represent a large population
affected by the deleterious consequences of chronic systemic
hypoxia. For many years, it was believed that the hypoxic state
confers cardioprotection and renders hearts more tolerant to
ischemia/reperfusion (I/R). However, it has been made clear that
it is not hypoxia, but rather the reoxygenation after hypoxia, the
real factor that confers cardioprotection. In facts, when exposed to
chronic systemic hypoxia without reoxygenation, hearts exhibit
marked deleterious alterations in several signaling paths, including
K+ATP channels [1], oxidative stress [2] and mitogen-activated
protein kinases [3]. Such changes are followed by right ventricle
dilatation with wall thickening [4], impaired tolerance to
reoxygenation [2] and impaired ability to resist ischemia/
reperfusion (I/R) injury [5]. These findings are corroborated by
the clinical observation that the outcome of surgery aimed at
repairing the cyanotic congenital heart defects is complicated by
myocardial damage occurring because of the acute re-oxygenation
at the moment of the institution of cardiopulmonary bypass with
elevated oxygen content, followed by the I/R injury when heart is
arrested to perform the intra-cardiac repair [6].
In principle, at least four treatments appear suitable to improve
cardioprotection in chronically hypoxic patients: ischemic precon-
ditioning, remote ischemic preconditioning, postconditioning and
intermittent hypoxia. Actually, each of them presents features that
prevent their full application in clinical contexts and the search for
alternative treatments is imperative. In rats exposed to chronic
systemic hypoxia for 2 weeks, daily reoxygenation events (or
intermittent reoxygenation, IntReox) enable hearts to resist to I/R
[5], perhaps as the result of modulation of some mitogen-activated
kinases, namely phosphatidylinositol-3-kinase-protein kinase B
(Akt) and extracellular signal-regulated kinases 1/2 (ERK1/2)
[7]. Although this finding potentially addresses IntReox as an
elective pretreatment to improve cardioprotection in hypoxic
hearts, even IntReox is difficult to be applied in the clinical
practice. Therefore, searching for pharmacological alternatives to
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IntReox may enable to devise a therapy whereby hypoxic patients
benefit from IntReox without the need of the reoxygenation.
The NO/cyclic GMP (cGMP) pathway is a preponderant,
although not exclusive, mechanism that mediates reoxygenation-
induced cardioprotection [8]. The rationale is that the NO produced
by endothelial cells activates smooth muscle cell soluble guanylate
cyclase to produce cGMP that acts as a vasodilator and hence as a
cardioprotective agent. As the intracellular level of cGMP is con-
trolled by the activity of phosphodiesterase-5 (PDE5), it is expected
that pharmacological inhibition of PDE5 by sildenafil might
improve cardioprotection in the hypoxic myocardium. A pharma-
cological stimulator of ischemic preconditioning [9–11], sildenafil
now represents a powerful therapeutical tool in several cardiovas-
cular disorders [12]. Well tolerated for long-term treatment with few
side-effects [13], sildenafil reduces pulmonary vascular resistance
[14], improves arterial oxygenation in patients with pulmonary
artery hypertension [15] and prevents altitude-induced hypoxemia
[16,17]. But the potential role of sildenafil to mimic the reoxygena-
tion-induced cardioprotection during hypoxia is still unexplored.
This study aims at testing the hypothesis that sildenafil admini-
stration during systemic hypoxia mimics the beneficial effects led by
IntReox. To this purpose, we will expose animals to chronic hypoxia
for 2 weeks and compare the resistance to acute myocardial infarct in
animals subjected to IntReox, sildenafil administration, or both.
Materials and Methods
Animals
A total of 109 male 5-week old Sprague-Dawley rats were
exposed to hypoxia (10% O2) for 15 days in specially designed
chambers that enable all kinds of treatments, including drugs
administration and animals handling avoiding any exposure of the
animals to atmospheric air [1,2]. Rats divided into four groups:
saline (n = 25), sildenafil (n = 22), IntReox (1-h normoxia per day,
n = 19) and treated with both sildenafil and IntReox (n = 17). Of
these, 6, 3 and 3 rats belonging to saline, sildenafil and IntReox
groups, respectively, died on the first day of hypoxia. Therefore,
final n was 19, 19, 22 and 17 rats in the four groups. Normoxic
rats breathing room air in the same chambers used for hypoxia
served as control (n = 20).
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Committee on the Ethics of Animal Experiments of
the Centre Hospitalier Universitaire Vaudoise (Permit Number:
1325. 2). All surgery was performed under sodium pentobarbital
anesthesia, and all efforts were made to minimize suffering.
Sildenafil was obtained from a 25-mg Viagra (Pfizer) tablet that
was dissolved in 21.6 ml saline, filtered and stored at 4uC. This
solution was given daily i. p. in the dose of 1.4 mg?kg21 b. w. dis-
solved in 0.3 ml saline. Rats had free access to water and a
laboratory diet until 24 h before sacrifice. For sacrifice, performed
24 h after the last aeration or administration of sildenafil, rats were
anesthetized (100 mg?kg21 thiopental and 1500 IU heparin i. p.) in
the compensation chamber kept at 10% O2. The study was con-
ducted in accordance with the Guide for the Care and Use of Laboratory
Animals, published by the National Institutes of Health (NIH
Publication No. 85-23, Revised 1996). Experimental protocols
conformed to Swiss law and local ethical committee guidelines for
animal research.
LAD ligature
This part of the study was performed in 36 animals (7 normoxic
and 29 hypoxia, including 7 saline, 8 treated with sildenafil, 8
IntReox and 6 sildenafil+IntReox). Anesthetized (100 mg?kg21
sodium pentobarbital+500 IU heparin i. p.) rats were placed on a
heating pad at 37uC and ventilated at 60 cycles?min21 with a tidal
volume of 2 ml (Harvard Apparatus model 683, Holliston, MA)
with either room air or hypoxic atmosphere for normoxic and
hypoxic groups, respectively. The left anterior descending coronary
artery (LAD) was occluded for 30 min [18] and reperfused for 3 h,
then the aorta was mounted on a cannula and perfused with 15–
20 ml saline at room temperature to wash out the blood. LAD was
re-occluded and saturated Evans blue (2 ml) injected to mark the
ischemic zone as tissue area without the blue dye. The heart was
frozen in liquid nitrogen and stored at 220uC until analysis.
To measure the infarct and risk areas, the frozen heart was cut
into five/six 1-mm thick transverse slices from apex to base. The
slices were incubated in triphenyltetrazolium chloride in sodium
phosphate buffer at 37uC for 20 min to stain viable cells in the risk
zone. Afterwards, the slices were immersed in 10% formalin for 4
days to enhance contrast between stained and unstained areas,
with the latter representing the infarct size. The extent of stained
and unstained areas was calculated for each slice from comput-
erized images using NIH Image software (National Institutes of
Health, USA). The risk area was expressed as percentage of total
ventricle area whereas the infarct area was expressed as a per-
centage of the risk area.
Biochemical analyses
This part of the study was performed in 27 animals (7 normoxic
and 20 hypoxia, including 5 saline, 5 treated with sildenafil, 5
IntReox and 5 sildenafil+IntReox). Anesthetized rats were
euthanized by removing heart and two blood samples were
withdrawn into a heparinized tube to measure either hemoglobin
concentration, hematocrit and red blood cell count (Abbott Cell-
dyn 3500 R System, Baar, Switzerland) or plasma nitrates+nitrites
(NOx) by the Griess reaction. The myocardium was quickly rinsed
in ice-cold PBS (pH 7.4), clamped between steel tongs pre-cooled
with liquid nitrogen and stored at 280uC until analysis.
The expression levels of eNOS and phosphorylated (P)-eNOS
were measured in homogenized frozen tissue by Western blotting
[18] using primary antibodies for eNOS (N-20: sc-653) and
phosphorylated eNOS (Ser1177) (Santa Cruz Biotechnology) on a
8% denaturating gel, followed by incubation with HRP-conjugat-
ed secondary antibody. The same extract was used for the
determination of Akt and P-Akt by phosphospecific antibodies
against P-Akt (Ser473) (Cell Signaling Technologies). Band
intensities were quantified by NIH AutoExtractor-1.51 software.
The same extract from a normoxic heart was loaded on all blots
for quantitative comparisons.
To measure cGMP, frozen tissue was homogenized at 4uC with
0.1 mol?l21 HCl (10% wet wt/vol), centrifuged (2000 rpm for
10 min at 4uC) and cGMP measured using an immunoassay kit
(Assay designs, Inc., MI). Caspase-3 activity was assayed by
Caspase-3/CPP32 colorimetric assay kit (MBL).
Immunofluorescence
Frozen biopsies were embedded in Optimum Cutting Temper-
ature Compound (Leica Instruments, Nussloch, Germany), serial
5-mm thick sections were obtained in a cryomicrotome (Leica
CM1510, Nussloch, Germany) and placed on silanized glass slides.
Two distinct sections were obtained from each biopsy, and five
fields were selected from each section. Care was taken in order to
analyze the same areain all sections. The sections were dried
(2 min at room temperature), fixed in 4% buffered formalin
(45 min), rinsed 3 times in PBS (5 min/each), post-fixed with
ethanol-acetic acid 2:1 (vol:vol) (5 min at 220uC), rinsed twice in
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PBS (5 min/each), boiled in 10 mM citrate at pH 6.0 (10 min),
washed once in H2O and twice in PBS, and finally used for
histochemistry.
To detect DNA fragmentation, we used the TUNEL ApopTag
Red In Situ Apoptosis detection kit (Chemicon, International).
The images were acquired and analyzed as described elsewhere
[19], counting the number of TdT-positive nuclei by examining
five random fields in a blind procedure. Values are expressed as
the ratio (number of TdT-positive nuclei)/(total number of nuclei).
The total number of nuclei was detected by Hoechst.
Morphologic measurements
This part of study was performed in 32 animals (6 normoxic and
26 hypoxia, including 5 saline, 6 treated with sildenafil, 9 IntReox
and 6 sildenafil+IntReox). For morphologic measurements, the
hearts were excised, excess water was absorbed on tissue paper, and
the heart mass was weighed. The atria were excised, and the free
walls of the RV and LV and the septum were dissected free, dried
for 48 hours at 90uC, and weighed separately. RV hypertrophy was
assessed from the weight ratio of the RV to LV plus interventricular
septum (IS) (RV/[LV+IS]).
Statistics
Data are expressed as mean6SEM. Significance level was
P= 0.05 (two-tailed). To detect differences among the groups, we
routinely performed one-way ANOVA. If this test resulted sig-
nificant, the differences between selected pairs of data were tested
using the Bonferroni procedure. Time courses were analyzed and
compared by the Mann-Whitney test.
Results
Body weight, cardiac hypertrophy and polycythemia
The weight of the animals after thetreatments was less in all
hypoxic groups compared to normoxia (Table 1). Within the
hypoxic groups, the various treatments attenuated, without
eliminating, the effect of hypoxia on body weight. Myocardial
hypertrophy, assessed from the heart/body weight ratio, increased
in hypoxic saline-treated rats (P,0.001 vs. normoxia). Whereas the
treatment with sildenafil attenuated such increase (P,0.001
sildenafil vs. saline), IntReox was ineffective (P=NS vs saline).
When the two treatments were combined, the heart/body weight
ratio returned to the normoxic value (P,0.001 vs. both saline-
treated and IntReox animals). Hematocrit, blood hemoglobin
concentration and red blood cell count were elevated in hypoxic
animals with respect to normoxic (P,0.0001 for all the parameters).
Both treatments were ineffective.
Tolerance to acute infarct
Figure 1 shows the effects of the various treatments on the risk
area and the infarct size after LAD ligation for 30 min and
reperfusion for 3 h. When expressed as percentage of total
ventricular area, the area at risk was the same in all the groups
(ANOVA P=NS). Thus, the stress imposed to the heart had the
same severity in all the groups. However, the infarct size,
expressed as percentage of the area at risk (ANOVA P=0.001),
was markedly increased in hypoxic with respect to normoxic
hearts (68.562.4% vs. 46.564.4%, P= 0.001). In vivo administra-
tion of sildenafil reduced the infarct size to 40.662.6% of the area
at risk (P = 0.001). IntReox animals displayed reduced infarct size
to 23.862.8% of the area at risk (P = 0.001). The reduction
afforded by IntReox was greater than that afforded by the
treatment with sildenafil (P = 0.01). When animals were treated
with both sildenafil and IntReox, the resulting pattern was the
same as that observed in IntReox hearts, with the infarct size
(23.562.8% of the area at risk) markedly reduced with respect to
both hypoxia (P= 0.001) and sildenafil (P = 0.01). Thus, both
sildenafil administration and IntReox protect from I/R injury, and
the combination of the two treatments apparently does not yield
any additional synergistic protection.
Apoptosis
We assessed this phenotype by measuring the extent of DNA
fragmentation by the TUNEL assay and the activation of caspase-3
(Figure 2). For both parameters, untreated chronic hypoxia in-
creased the degree of apoptosis, whereas all treatments attenuated
the effects of hypoxia by reducing the degree of apoptosis. In no
case, however, the effects of hypoxia were completely reversed.
Thus, both treatments enabled control of hypoxia-induced apopto-
sis, but without additional synergistic effects.
Biochemical analyses
The myocardial cGMP level was depressed by hypoxia with
respect to normoxia (0.4360.10 pmol?ml21 vs. 1.2060.31
pmol?ml21, respectively, P = 0.01, Figure 3, top panel). Both in
vivo administration of sildenafil and IntReox restored the cGMP
level. The combined treatments did not further increase cGMP.
Table 1. Animal and hematological measurements.
Normoxia Chronic hypoxia
Saline Sildenafil IntReox Sildenafil+IntReox
Initial body weight, g 25162 24865 25569 25065 23566
Gain in body weight, g 9867 24610* 73621# 1664$ 2565#
Heart/body weight, mg?g21 3.7660.11 5.5760.22* 4.2860.21# 5.2160.09$ 3.7560.16#
Hematocrit 0.5160.02 0.6660.02* 0.6560.01 0.6860.01 0.6260.01
Hemoglobin, g?l21 15864 20067* 20265 21863 20564
Red blood cell count, RBC?fl21 8.6560.36 10.4560.43* 10.0560.29 9.8060.19 9.4060.18
*, P,0.05 when comparing untreated chronic hypoxia vs. normoxia;
#, P,0.05 when comparing the various treatments vs. untreated chronic hypoxia;
$, P,0.05 when comparing the two treatments between them. All post-tests performed with the Bonferroni method.
Data are mean6SEM.
ANOVA P,0.0001 for all measurements.
doi:10.1371/journal.pone.0027910.t001
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By contrast, the myocardial NOx level (Figure 3, bottom panel)
remained unaffected by the treatments.
The plasma level of NOx, an index of NO production,
increased markedly during hypoxia from 4.561.0 mmol?l21 to
8.760.9 mmol?l21 (P = 0.001, Figure 3, middle panel). In vivo
administration of sildenafil further increased NOx (P= 0.05). By
contrast, IntReox did not cause a significant increase of NOx with
respect to saline-treated animals. Combining sildenafil with
IntReox led to a substantially higher NOx (P= 0.001 vs. sildenafil
and aeration). Thus, whereas hypoxia increased NO production,
sildenafil enabled further increase of this parameter, but IntReox
alone could not increase appreciably NOx.
Nitric oxide synthase
To address the expression level of eNOS and its phosphoryla-
tion, Figure 4, top panel, shows that eNOS expression was
unaffected by hypoxia as well as the various treatments. By
contrast, phosphorylated eNOS was decreased in hypoxic with
respect to normoxic hearts (P = 0.05, Figure 4, bottom panel). Both
treatments restored the normoxic eNOS phosphorylation
(P = 0.05). Despite a slight reversal of the effect led by sildenafil
and IntReox, their combination did not change significantly the
pattern (P=NS). Thus, both treatments enhanced eNOS
phosphorylation, but without effects on eNOS expression.
Akt signaling
Figure 5, top panel, shows that, like eNOS expression, total Akt
expression was unaffected by neither hypoxia nor the various
treatments. By contrast, phosphorylated Akt decreased in hypoxic
with respect to normoxic hearts (P = 0.0001). Both treatments led
to overshooting P-Akt (P = 0.0001), with no additional effect due to
the combination of the treatments (P =NS).
Discussion
Exposure of animals to chronic systemic hypoxia for 15 days
depressed their resistance to acute myocardial infarct. Either
IntReox or administration of sildenafil during hypoxia reverted
such deleterious effect without affecting polycythemia and with
negligible effects of animal homeostasis. This phenotype was
paralleled by changes in apoptosis, myocardial cGMP, P-Akt and
P-eNOS. No cumulative effect of the combination of the
treatments was observed, with the exception of plasma NOx. As
both the reoxygenation and sildenafil increased plasma NOx,
myocardial cGMP and eNOS Ser1177 phosphorylation, the up-
regulation of the NO/cGMP signaling pathway appears to be a
critical factor to enhance tolerance to acute myocardial infarct
during hypoxia.
Sildenafil-induced cardioprotection
A key issue in our study, the hypoxia-induced impairment of
cardioprotection confirms previously reported data [5]. Likewise,
IntReox has the potential to improve myocardial tolerance to I/R,
and is mimicked by treatment with sildenafil.
Although several studies have focused into the role of PDE5
inhibition on I/R injury in normoxia [10,20–22], this is to our
knowledge the first report demonstrating that sildenafil adminis-
tration during systemic hypoxia is cardioprotective. We tested a
single sildenafil dose within the range that saturates protection in
humans [23]. Despite the plasma half-life of 4–6 h [24], the
selected dose substantially elevated myocardial cGMP, indicative
of efficient inhibition of PDE5 activity. High cGMP leads to acute
and delayed cardioprotection via mitochondrial K+ATP channels
opening [25] and mediates preconditioning in rat hearts [11]. In a
normoxic model of I/R, sildenafil was shown to induce delayed
Figure 1. Tolerance to acute infarct. Hearts were subjected to 30-min occlusion of the left anterior descending coronary artery followed by 3-h
reperfusion, and were stained as described in Materials and Methods. The left panel shows sample photographs of the central sections of one heart
per group. The right panel shows average area at risk (top) and infarct size (bottom) along withvalues obtained in single experiments. The P value in
the insets reports ANOVA. *, P,0.05 when comparing untreated chronic hypoxia vs. normoxia;#, P,0.05 when comparing the various treatments vs.
untreated chronic hypoxia; $, P,0.05 when comparing the two treatments between them. All post-tests performed with the Bonferroni method.
doi:10.1371/journal.pone.0027910.g001
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preconditioning by elevating iNOS and eNOS mRNA and
proteins levels [26]. We didn’t observe any elevation in eNOS,
but the difference in the experimental models, acute vs. chronic
hypoxia, may account for this discrepancy. Furthermore, our data
are consistent with constant eNOS, as opposed to increased P-
eNOS, in chronically hypoxic mice irrespectively of sildenafil [27].
In a model of rabbit hypoxic from birth that involved myocardial
reoxygenation, eNOS phosphorylation at Ser1177 increased [28],
consistently with our data that show greater P-eNOS in reoxyge-
nated than hypoxic hearts. Although eNOS can be phosphorylated
in multiple sites, its phosphorylation at Ser1177, as probed in this
study, indicates the effective degree of electron flow through eNOS
[29].
Apoptosis is crucial in determining cardioprotection. Chronic
hypoxia enhances cardiomyocytes apoptosis [30], in part through
stress-activated protein kinases/c-Jun NH2-terminal kinases 1 and
2 (JNKs) and p38 MAPK [27]. Here, PDE5 inhibitiondecreased
pro-apoptotic caspase-3 and DNA fragmentation, in agreement
with work documenting that PDE5 inhibition modulates the
pathways operating through p38, ERK1/2 and NO [26,31]. It is
unlikely, however, that increased apoptosis represents the only
cause for worse tolerance to ischemia, because IntReox animals
treated with sildenafil failed to further decrease apoptosis, yet the
infarct size was less than in either IntReox and sildenafil-treated
animals.
Reoxygenation-induced cardioprotection
The finding that IntReox is protective against I/R addresses the
relevance of the paths activated by sildenafil to induce cardiopro-
tection. Up-regulation of cGMP in the absence of PDE5 inhibition
points to NO-driven stimulation of soluble guanylate cyclase as
regulator of intracellular cGMP in addition to PDE5 inhibition.
Perhaps IntReox enhances the expression of some isoforms of NO
synthase in endothelial cells, which escapes the methods used and
is out of the aims of this study. However, the effects of IntReox and
sildenafil were not cumulative, probably because the system was
already saturated by either treatment.
A matter of concern in Figure 3, plasma NOx was increased in
Sild+IntReox with respect to Sildenafil and IntReox, whereas
myocardial cGMP remained constant. First, the occurrence of a
linear relationship between plasma NOx and myocardial cGMP is
unlikely. Second, the possibility that cell cGMP levels off at
approximately 1–1.5 pmol/ml can’t be ruled out as this value was
never trespassed in our experiments. Indeed, even when sildenafil
was administered in normoxic rats (experiments not shown),
cGMP remained constant (1.3460.18 vs. 1.3560.21 pmol/ml,
Figure 2. Apoptosis. The left panel shows representative immunofluorescence images from the various groups under study. TdT-positive nuclei
are marked in red, whereas total nuclei are marked in blue. Overlap red+blue gives pink. Magnification 406, the bar represents 20 mm. Right top
panel. The left axis reports the percent of TdT-positive/total nuclei in all the samples (five sections per each biopsy, and five fields per each section).
In the Right bottom panel, the activation of caspase-3 activity is reported. The P value in the insets reports ANOVA. Sample photographs of the
central sections of one heart per group are shown. *, P,0.05 when comparing untreated chronic hypoxia vs. normoxia; #, P,0.05 when comparing
the various treatments vs. untreated chronic hypoxia; $, P,0.05 when comparing the two treatments between them. All post-tests performed with
the Bonferroni method.
doi:10.1371/journal.pone.0027910.g002
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P=NS) despite increased plasma NOx from 4.560.1 to
7.7961.06 mM (P,0.001). The myocardial NOx level was
insensitive to the various experimental conditions probably because
of fast scavenging of intracellular NO by NO-binding proteins.
As Akt blockade with LY-294002 reverted the protection
afforded by IntReox [7], we verified whether the mechanisms
underlying protection in sildenafil and IntReox groups share
similar pathways, and found similar changes in P-Akt in both
groups.
The delayed cardioprotective mechanism linked with IntReox
might share several features with those related to intermittent
hypoxia [32]. The potentially involved mechanisms include up-
regulation of NO production by eNOS [33] and down-regulation
of intracellular calcium by mitochondrial K+ATP channels opening
[34,35] (but a report shows that K+ATP channels are not
responsible for increased tolerance after hypoxia [36]). Further-
more, transcriptional and/or post-translational changes in endo-
plasmic reticulum calcium cycling proteins might occur [37,38], as
well as increased expression of vascular endothelial growth factor
and its receptors [39], which may lead to the control of apoptosis
with improved cell viability [40]. IntReox might recruit analogous
mechanisms. In facts, IntReox has been shown to recover heart
K+ATP channels [1] and mitogen-activated protein kinases [3], as
well as skeletal muscle immunoreactivity to heat-shock protein-70,
heme-oxygenase-1 [41] and cytochrome c oxidase [42]. These
features would in principle lead to cardioprotection, independently
of polycythemia and cardiomyocyte morphology [4].
Conclusion
Exposure to chronic systemic hypoxia for 15 days markedly
depresses myocardial tolerance to acute myocardial infarct. Either
inhibition of PDE5 by sildenafil during hypoxia or IntReox
attenuate this effect, but the mechanisms do not appear to be
cumulative. The observed patterns are associated with improved
NO metabolism and reduced activation of apoptotic pathways.
Figure 3. Effects of NO. Myocardial level of cGMP (top panel), plasma
level of nitrates/nitrites (middle panel) and myocardial nitrates/nitrites
level (botton panel). The P value in the insets reports ANOVA. *, P,0.05
when comparing untreated chronic hypoxia vs. normoxia; #, P,0.05
when comparing the various treatments vs. untreated chronic hypoxia.
All post-tests performed with the Bonferroni method.
doi:10.1371/journal.pone.0027910.g003
Figure 4. eNOS activity. The left panel shows representative Western blots performed using antibodies against total eNOS protein and
phosphorylated eNOS, with b-actin as loading control. All blots were subjected to densitometry and the right panel shows the average expression of
total eNOS (top) and phosphorylated eNOS (bottom). The P value in the insets reports ANOVA. *, P,0.05 when comparing untreated chronic hypoxia
vs. normoxia;#, P,0.05 when comparing the various treatments vs. untreated chronic hypoxia. All post-tests performed with the Bonferroni method.
doi:10.1371/journal.pone.0027910.g004
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Thus, in vivo sildenafil treatments may have a good potential
application in targeting systemic hypoxia-induced derangement of
cardiovascular function.
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